Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
